Patent · US Active

Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant

US12122819B2 · kind B2 · utility

0Cited by

24References

14Claims

0Family size

Assignee

Silver Creek Pharmaceuticals, Inc. · US

Inventors

Laura D.J. Antipov · Oakland, US
Shawdee Eshghi · Oakland, US
Kristopher M. Kuchenbecker · San Francisco, US
Bjorn L. Millard · Orinda, US
Matthew Onsum · Corona, US
Andrea D. Nickerson · San Francisco, US
Timothy R. Stowe · San Francisco, US
Yan Zhang · San Francisco, US

Key dates

Filing date	Feb 10, 2022
Grant date	Oct 22, 2024
Priority date	—
Expiry date	Apr 22, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.